These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 32537843

  • 1. Evaluation of a simple image-based tool to quantify facial erythema in rosacea during treatment.
    Logger JGM, de Jong EMGJ, Driessen RJB, van Erp PEJ.
    Skin Res Technol; 2020 Nov; 26(6):804-812. PubMed ID: 32537843
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.
    Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N.
    Br J Dermatol; 2019 May; 180(5):1050-1057. PubMed ID: 30500065
    [Abstract] [Full Text] [Related]

  • 4. Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea.
    Pakdaman SF, Samadi A, Fattahi M, Naeimifar A, Ardehali FA, Ketabi Y, Nasrollahi SA, Firooz A.
    J Cosmet Dermatol; 2024 Sep; 23(9):2973-2981. PubMed ID: 38831548
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
    Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G.
    J Am Acad Dermatol; 2018 Jun; 78(6):1156-1163. PubMed ID: 29409914
    [Abstract] [Full Text] [Related]

  • 7. Clinical and erythema-directed imaging evaluation of papulo-pustular rosacea with topical ivermectin: a 32 weeks duration study.
    Dall'Oglio F, Lacarrubba F, Luca M, Boscaglia S, Micali G.
    J Dermatolog Treat; 2019 Nov; 30(7):703-707. PubMed ID: 30663445
    [Abstract] [Full Text] [Related]

  • 8. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
    Baumann L, Goldberg DJ, Stein Gold L, Tanghetti EA, Lain E, Kaufman J, Weng E, Berk DR, Ahluwalia G.
    J Drugs Dermatol; 2018 Mar 01; 17(3):290-298. PubMed ID: 29537447
    [Abstract] [Full Text] [Related]

  • 9. A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin.
    Baldwin H, Santoro F, Lachmann N, Teissedre S.
    J Cosmet Dermatol; 2019 Dec 01; 18(6):1686-1692. PubMed ID: 30803131
    [Abstract] [Full Text] [Related]

  • 10. Rosacea with persistent facial erythema and high Demodex density effectively treated with topical ivermectin alone or combined with oral carvedilol.
    Huang HP, Hsu CK, Lee JY.
    Dermatol Ther; 2021 Mar 01; 34(2):e14899. PubMed ID: 33605018
    [Abstract] [Full Text] [Related]

  • 11. Skin compatibility and efficacy of a cosmetic skin care regimen with licochalcone A and 4-t-butylcyclohexanol in patients with rosacea subtype I.
    Schoelermann AM, Weber TM, Arrowitz C, Rizer RL, Qian K, Babcock M.
    J Eur Acad Dermatol Venereol; 2016 Feb 01; 30 Suppl 1():21-7. PubMed ID: 26805419
    [Abstract] [Full Text] [Related]

  • 12. Ivermectin treatment in rosacea: How novel smartphone technology can support monitoring rosacea-associated signs and symptoms.
    Schaller M, Riel S, Bashur R, Kurup N, Schnidar H, Fehrenbacher B.
    Dermatol Ther; 2022 Nov 01; 35(11):e15869. PubMed ID: 36177738
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
    Kuang AW, DuBois J, Attar M, Ahluwalia G.
    J Drugs Dermatol; 2018 Feb 01; 17(2):213-220. PubMed ID: 29462230
    [Abstract] [Full Text] [Related]

  • 17. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
    Kircik LH, DuBois J, Draelos ZD, Werschler P, Grande K, Cook-Bolden FE, Weng E, Berk DR, Ahluwalia G.
    J Drugs Dermatol; 2018 Jan 01; 17(1):97-105. PubMed ID: 29320594
    [Abstract] [Full Text] [Related]

  • 18. Inter-observer evaluation of erythema-directed photography for the assessment of erythema and telangiectasias in rosacea.
    Dall'Oglio F, Verzi AE, Lacarrubba F, Giuffrida G, Milani M, Micali G.
    Skin Res Technol; 2021 Jul 01; 27(4):521-525. PubMed ID: 33141958
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study.
    El-Domyati M, Rezk AF, Nasif G, Abdelhameed SS, Medhat W.
    Int J Dermatol; 2023 Jul 01; 62(7):888-894. PubMed ID: 37212604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.